BDX
59
3
BK
60
2
SNA
56
3
FTI
61
5
HES
49
2
EMN
40
5
KEY
24
2
JBHT
46
4
COF
48
3
PHM
44
4
TMO
52
8
CINF
24
-8
DD
44
2
TAP
57
6
XOM
33
3
FITB
36
3
AEP
45
5
MAT
41
2
FOX
71
3
CHRW
53
2
BDX
59
3
BK
60
2
SNA
56
3
FTI
61
5
HES
49
2
EMN
40
5
KEY
24
2
JBHT
46
4
COF
48
3
PHM
44
4
TMO
52
8
CINF
24
-8
DD
44
2
TAP
57
6
XOM
33
3
FITB
36
3
AEP
45
5
MAT
41
2
FOX
71
3
CHRW
53
2
Financhill
Back

Biomarin Pharmaceutical 10K Form

Buy
60

BMRN
Biomarin Pharmaceutical

Last Price:
$65.65
Seasonality Move:
5.39%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2024-04-26 10Q BMRN/Biomarin Pharmaceutical Quarterly
2024-02-26 10K BMRN/Biomarin Pharmaceutical Annual
2023-11-02 10Q BMRN/Biomarin Pharmaceutical Quarterly
2023-08-02 10Q BMRN/Biomarin Pharmaceutical Quarterly
2023-04-28 10Q BMRN/Biomarin Pharmaceutical Quarterly
2023-02-27 10K BMRN/Biomarin Pharmaceutical Annual

Receive BMRN News And Ratings

See the #1 stock for the next 7 days that we like better than BMRN

BMRN Financial Statistics

Sales & Book Value

Annual Sales: $2.4B
Cash Flow: $200.3M
Price / Cash Flow: 42.87
Annual Sales: $28.41
Price / Book: 2.31

Profitability

EPS (TTM): 1.67000
Net Income (TTM): $322.3M
Gross Margin: $1.9B
Return on Equity: 6.29%
Return on Assets: 4.69%

Biomarin Pharmaceutical Earnings Forecast

Key Biomarin Pharmaceutical Financial Ratios

  • The Gross Profit Margin over the past 26 years for BMRN is 78.72%.
  • The Selling, General & Administrative Expenses for BMRN have been equal to 38.74% of Gross Profit Margin.
  • The Research & Development expenses have been 30.87% of Revenue.
  • The Interest Expense is 9.99% of Operating Income.
  • The Net Earning history of BMRN is 6.93% of Total Revenues.
  • Per Share Earnings over the last 26 years have been positive in 14 years.

Biomarin Pharmaceutical Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: BMRN
CUSIP: 09061G
Website: biomarin.com

Debt

Debt-to-Equity Ratio: 0.11
Current Ratio: 4.27
Quick Ratio: 2.39

Price-to-Earnings

Trailing P/E Ratio: 75.51
Forward P/E Ratio: 15.75

BMRN Technical Analysis vs Fundamental Analysis

Buy
60
Biomarin Pharmaceutical (BMRN) is a Buy

Is Biomarin Pharmaceutical a Buy or a Sell?